Phase 1 Study of Lenalidomide and Ibrutinib in Combination with Rituximab in Relapsed and Refractory CLL and SLL

被引：0
|
作者：
Ujjani, Chaitra S.
Wang, Hongkun
Skarbnik, Alan P.
Trivedi, Neel
Ramzi, Pari
Khan, Nadia
Cheson, Bruce D.
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4324
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL
    Ujjani, Chaitra
    Wang, Hongkun
    Skarbnik, Alan
    Trivedi, Neel
    Ramzi, Pari
    Khan, Nadia
    Cheson, Bruce D.
    BLOOD ADVANCES, 2018, 2 (07) : 762 - 768
  • [2] Ibrutinib In Combination With Bendamustine and Rituximab Is Active and Tolerable In Patients With Relapsed/Refractory CLL/SLL: Final Results Of a Phase 1b Study
    Brown, Jennifer R.
    Barrientos, Jaqueline C.
    Barr, Paul M.
    Flinn, Ian
    Burger, Jan A.
    Salman, Zeena
    Clow, Fong
    James, Danelle F.
    Graef, Thorsten
    Friedberg, Jonathan W.
    Rai, Kanti R.
    O'Brien, Susan
    BLOOD, 2013, 122 (21)
  • [3] A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL
    J R Brown
    J Abramson
    E Hochberg
    E Mikler
    V Dalton
    L Werner
    H Reynolds
    C Thompson
    S M McDonough
    Y Kuang
    J Ritz
    D Neuberg
    A S Freedman
    Leukemia, 2010, 24 : 1972 - 1975
  • [4] A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL
    Brown, J. R.
    Abramson, J.
    Hochberg, E.
    Mikler, E.
    Dalton, V.
    Werner, L.
    Reynolds, H.
    Thompson, C.
    McDonough, S. M.
    Kuang, Y.
    Ritz, J.
    Neuberg, D.
    Freedman, A. S.
    LEUKEMIA, 2010, 24 (11) : 1972 - 1975
  • [5] Combination therapy with etanercept and rituximab in relapsed CLL/SLL
    Woyach, J. A.
    Lucas, M. S.
    Heerema, N. A.
    Moran, M. E.
    Lucas, D. M.
    Young, D.
    Caligiuri, M. A.
    Lin, T. S.
    Byrd, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] A Phase I Study of Lenalidomide in Combination with Fludarabine-Rituximab in Previously Untreated CLL/SLL.
    Brown, Jennifer R.
    Abramson, Jeremy S.
    Hochberg, Ephraim P.
    Mikler, Evgeny
    Dalton, Virginia
    Reynolds, Hazel
    Romano, Jennifer
    Werner, Lillian
    Thompson, Christina
    McDonough, Sean
    Ritz, Jerome
    Neuberg, Donna
    Freedman, Arnold S.
    BLOOD, 2009, 114 (22) : 1330 - 1331
  • [7] Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
    Siddiqi, Tanya
    Soumerai, Jacob D.
    Dorritie, Kathleen A.
    Stephens, Deborah M.
    Riedell, Peter A.
    Arnason, Jon
    Kipps, Thomas J.
    Gillenwater, Heidi H.
    Gong, Lucy
    Yang, Lin
    Ogasawara, Ken
    Thorpe, Jerill
    Wierda, William G.
    BLOOD, 2022, 139 (12) : 1794 - 1806
  • [8] Pirtobrutinib in Relapsed or Refractory CLL and SLL
    Woyach, Jennifer A.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (05) : 230 - 231
  • [9] A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma
    Wang, Luhua
    Fayad, Luis
    Hagemeister, Fredrick B.
    Neelapu, Sattva
    Samaniego, Felipe
    McLaughlin, Peter
    Samuels, Barry
    Yi, Qing
    Pro, Barbara
    Fanale, Michelle
    Shah, Jatin
    Younes, Anas
    Bell, Neda
    Knight, Robert
    Zeldis, Jerome B.
    Cabanillas, Fernando
    Kwak, Larry
    Romaguera, Jorge
    BLOOD, 2009, 114 (22) : 1064 - 1065
  • [10] A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL
    Crombie, Jennifer L.
    Tyekucheva, Svitlana
    Savell, Alexandra
    Francoeur, Karen
    Choiniere, Mark
    Montegaard, Josie
    Soumerai, Jacob D.
    Arnason, Jon E.
    Fisher, David C.
    Brown, Jennifer R.
    Davids, Matthew S.
    BLOOD, 2019, 134
12345